Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932022 · ClinicalTrials.gov registry record · Phase 4
Trospium Chloride XR in Obese Female Patients With Overactive Bladder
A Phase 4 study of Obesity and Overactive Bladder, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 127
- Enrollment target
- 1
- Study location
NCT00932022 is a Phase 4 study of Obesity and Overactive Bladder that has completed, run by Allergan. The registered enrollment target is 127 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00932022, a Phase 4 study of Obesity and Overactive Bladder, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 127 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only. The study assessed the change from baseline in urinary frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The study was 14 weeks in duration.
Conditions Studied
Interventions
- OTHER placebo
- DRUG Trospium Chloride, Extended Release (XR)
Study Locations (1)
California
- - La Mesa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00932022
The ClinicalTrials.gov registry entry for NCT00932022 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (84% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00932022 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00932022 about?
NCT00932022 is a clinical study titled "Trospium Chloride XR in Obese Female Patients With Overactive Bladder". This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only. The study assessed the change from baseline in urinary frequency, urgency, and incontin...
What is the current status of trial NCT00932022?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 127 participants. The study started on 2009-07. Estimated completion is 2011-12.
What conditions does trial NCT00932022 study?
This clinical trial studies the following conditions: Obesity, Overactive Bladder, Incontinence.
What interventions are being tested in trial NCT00932022?
The interventions under investigation include: placebo (OTHER), Trospium Chloride, Extended Release (XR) (DRUG).
Who is sponsoring clinical trial NCT00932022?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00932022 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.